Revenue: As of FY2025 Q1, the actual value is USD 9.2 M.

Segment Revenue

• Revenue for the first quarter of 2025 was approximately $9.2 million, driven solely by the TriNav® Infusion System, representing a growth of approximately 42% compared to the first quarter of 2024.

Outlook / Guidance

• The company anticipates receiving aggregate gross proceeds from the Private Placement of approximately $22.0 million, before deducting estimated offering fees and expenses. The Private Placement is expected to close on May 2, 2025, but no later than May 7, 2025, subject to customary closing conditions. TriSalus Life Sciences anticipates that the private placement will fund the business to profitability and accelerate applications already in use and new potential applications. The Company expects to launch the exchange offer by the end of Q2 2025 and hold a special meeting in Q3 2025 to vote on amendments to the Certificate of Designations for the Preferred Stock.